scholarly journals Clinical characteristics and risk factors of intestinal involvement in Behçet’s syndrome patients: a cross-sectional study from a single center

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Cheng-cheng Hou ◽  
Jing-fen Ye ◽  
Hai-fen Ma ◽  
Jian-long Guan
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Clinical Characteristics ◽  
Behçet’S Syndrome ◽  
Laboratory Parameters ◽  
Behçet's Syndrome ◽  
Amyloid A ◽  
Intestinal Involvement ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

Abstract Background Intestinal Behçet’s syndrome (BS) has high morbidity and mortality rates with serious complications. The purpose of this study was to investigate the clinical characteristics and laboratory parameters of intestinal and mucocutaneous BS patients and analyze the risk factors of intestinal involvement in BS patients. Methods A retrospective analysis was used to collect the demographic data and laboratory parameters from 97 intestinal and 154 mucocutaneous BS patients. Univariate and multivariate logistic regression analyses were used to investigate the risk factors of intestinal involvement in BS patients. Results The most common clinical manifestations of first onset in intestinal BS patients were oral ulceration (100.00%), followed by genital ulcers (62.89%) and erythema nodule (28.87%), gastrointestinal lesions (28.87%), pseudofolliculitis (25.77%), fever (17.53%), arthritis (16.49%), ocular involvement (5.15%), while the least common were vascular involvement (2.06%) and hematologic involvement involvement (2.06%). The most common intestinal segment involved in intestinal BS patients was terminal ileum (30.9%), followed by ileocecal (18.6%), colon (15.5%). By univariate logistic regression analysis, gender, age at hospitalization, age of disease onset, BDCAF, T-SPOT, fever, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), leukocyte, erythrocyte, hemoglobin (HGB), neutrophil-to-lymphocyte ratio, serum amyloid A, complement 3, albumin, total cholesterol, high-density lipoprotein and interleukin 6 (IL-6) were found all risk factors of intestinal involvement in BS patients (P < 0.05 or P = 0.00). Moreover, gender (male), BDCAF (≥ 2), ESR (≥ 15 mm/H), CRP (> 10 mg/L), HGB (< 130 g/L) and IL-6 (> 7 pg/ml) were found the independent risk factors of intestinal involvement in BS patients (all P < 0.05). Conclusions More attention shall be paid to gender, BDCAF, ESR, CRP, HGB and IL-6 in BS patients. When gender (male), BDCAF (≥ 2), ESR (≥ 15 mm/H), CRP (> 10 mg/L), HGB (< 130 g/L) and IL-6 (> 7 pg/ml) being observed, it may reminds that the presence of intestinal involvement in BS patients.

scholarly journals Clinical Characteristics and Risk Factors of Intestinal Involvement in Behçet’s Syndrome Patients：A Cross-Sectional Study from a Single Center

2020 ◽  
Author(s):  
Cheng-cheng Hou ◽  
Jing-fen Ye ◽  
Hai-fen Ma ◽  
Jian-Long Guan
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Clinical Characteristics ◽  
Demographic Data ◽  
Behçet’S Syndrome ◽  
Newly Diagnosed ◽  
Behçet's Syndrome ◽  
Intestinal Involvement ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

Abstract Background: Intestinal Behçet’s syndrome (BS) has high morbidity and mortality rates with serious complications. This study aimed to investigate the clinical characteristics and laboratory indicators of intestinal BS compared with mucocutaneous BS patients in China and analyzed the risk factors of intestinal complications in BS patients.Methods: A retrospective analysis was used to collect the demographic data and laboratory results from 97 patients newly diagnosed with intestinal BS and 154 patients newly diagnosed with mucocutaneous BS. Univariate and multivariate logistic regression analyses were used to analyze the demographic data and laboratory indexes whether a risk factor of intestinal involvement in BS patients.Results: The most common clinical manifestations of first onset in intestinal BS patients were oral ulceration (100.00%), followed by genital ulcers (62.89%) and erythema nodule (28.87%), gastrointestinal lesions (28.87%), pseudofolliculitis (25.77%), fever (17.53%), arthritis (16.49%), ocular involvement (5.15%), while the least common were vascular involvement (2.06%) and blood system involvement (2.06%). The most common intestinal segment involved in intestinal BS patients was terminal ileum (30.9%), followed by ileocecal (18.6%), colon (15.5%). Most intestinal BS patients (89.7%) used ≥ 3 immunosuppressants to control disease while most mucocutaneous BS patients (92.9%) used 1 or 2 immunosuppressant. By univariate logistic regression analysis, we found gender, age at hospitalization, age of disease onset, BDCAF, T-SPOT, fever, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white blood cell (WBC), red blood cells (RBC), hemoglobin (HGB), neutrophil-to-lymphocyte ratio (NLR), serum amyloid A (SAA), complement 3 (C3), albumin, total cholesterol(TCH), high-density lipoprotein(HDL) and interleukin 6 (IL-6) were all risk factors of intestinal involvement in BS patients (P<0.05 or P=0.00). Additionally, gender (male), BDCAF (≥2), ESR (≥15mm/H), CRP (>10mg/L), HGB (<130g/L) and IL-6 (>7pg/ml) were the independent risk factors of intestinal involvement in BS patients (all P<0.05).Conclusions: More attention should be paid to gender, BDCAF, ESR, CRP, HGB and IL-6 of intestinal involvement in BS patients and therapeutic regiment should be adjusted timely to prevent the occurrence of serious clinical complication in BS patients.

Analysis of vascular involvement in 460 patients with Behçet's syndrome: Clinical characteristics and associated factors

2021 ◽  
pp. 105277
Author(s):  
Murat Torgutalp ◽  
Didem Sahin Eroglu ◽  
Serdar Sezer ◽  
Mucteba E Yayla ◽  
Gokturk Karatas ◽  
...  
Keyword(s):  
Associated Factors ◽  
Clinical Characteristics ◽  
Vascular Involvement ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

scholarly journals Predictors of Infliximab Refractory Intestinal Behçet’s Syndrome: A Retrospective Cohort Study from the Shanghai Behçet’s Syndrome Database

2021 ◽  
Author(s):  
Hua-fang Bao ◽  
Cheng-cheng Hou ◽  
Bo Ye ◽  
Jun Zou ◽  
Dan Luo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Protective Factor ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Independent Risk Factors ◽  
Behcet's Syndrome

ABSTRACT Objectives This retrospective cohort study aimed to find out predictors and early biomarkers of Infliximab (IFX) refractory Intestinal Behçet’s Syndrome (intestinal BS). Methods We collected the baseline clinical characteristics, laboratory parameters and concomitant therapies of intestinal BS patients treated by IFX from the Shanghai Behçet’s syndrome database. After 1-year IFX therapy, intestinal BS patients with non-mucosal healing (NMH, intestinal ulcers detected by colonoscopy) and/or no clinical remission [NCR, scores of the disease activity index for intestinal Behçet’s disease (DAIBD) ≥ 20] was defined as IFX refractory intestinal BS. Multivariate logistic regression analysis was performed to evaluate the predictors for NMH and NCR in IFX refractory intestinal BS. Results In 85 intestinal BS patients, NMH was identified in 29 (34.12%) patients, and NCR was confirmed in 20 (23.53%) patients. ESR (≥ 24mm/h) and fT3 (≤ 3.3pmol/L) were the independent risk factors of NMH in IFX refractory intestinal BS. Drinking alcohol and the fT3/fT4 ratio (≤ 0.24) were independent risk factors, and thalidomide was an independent protective factor, for NCR in intestinal BS patients treated by IFX. Conclusion This study may be applicable for adjusting the therapeutic strategy and sidestepping unnecessary exposure to IFX in intestinal BS patients. Routine assessments of ESR, fT3 and fT3/fT4 ratio are helpful to identify high-risk individuals of IFX refractory intestinal BS. Thalidomide is suggested to be a concomitant therapy with IFX for intestinal BS patients.

scholarly journals The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet’s syndrome

2021 ◽  
Author(s):  
Guzin Ozcifci ◽  
Tahacan Aydin ◽  
Zeynep Atli ◽  
Ilker Inanc Balkan ◽  
Fehmi Tabak ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

Clinical characteristics of pulmonary artery involvement in patients with Behçet’s syndrome: single-centre experience of 61 patients

2021 ◽  
Author(s):  
Didem Sahin Eroglu ◽  
Murat Torgutalp ◽  
Serdar Baysal ◽  
Anil Colaklar ◽  
Serdar Sezer ◽  
...  
Keyword(s):  
Pulmonary Artery ◽  
Clinical Characteristics ◽  
Behçet’S Syndrome ◽  
Single Centre ◽  
Behçet's Syndrome ◽  
Single Centre Experience ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

Behcet's syndrome

1970 ◽  
Vol 102 (1) ◽  
pp. 116-117 ◽  
Author(s):  
J. L. Fromer
Keyword(s):  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome

Poliomyelitis vaccine in the treatment of Behcet's syndrome

1980 ◽  
Vol 116 (12) ◽  
pp. 1348a-1348 ◽  
Author(s):  
B. Fishel
Keyword(s):  
Behçet’S Syndrome ◽  
Behçet's Syndrome ◽  
Poliomyelitis Vaccine ◽  
Behcet’S Syndrome ◽  
Behcet's Syndrome
Sign in / Sign up

Export Citation Format

Share Document